文献速递中医内科中药与中成药合理使用

复方贞术调脂胶囊治疗2型糖尿病合并非酒精性脂肪肝的分子机制:网络药理学与小型猪验证

Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
PubMed 文献 · J Ethnopharmacol · 2021-03-23

本研究采用网络药理学预测复方贞术调脂胶囊(FTZ)治疗2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的活性成分与靶点,并在小型猪模型验证。结果发现116个活性化合物和82个相关靶点,FTZ可调节PI3K-AKT、HIF-1α等代谢通路,动物实验显示FTZ降低TG、TC、LDL-C和FBG,升高HDL-C,改善胰岛素抵抗和肝损伤,机制与增加PI3K-AKT磷酸化、降低HIF-1α表达有关。

要点

  • FTZ可能通过调控PI3K-AKT和HIF-1α通路改善T2DM伴NAFLD。
  • 动物实验显示FTZ降低TG、TC、LDL-C和FBG,升高HDL-C。
  • FTZ减轻肝脏脂肪变性和脂质积累,改善胰岛素抵抗。

核心结论

  • 网络药理学与小型猪实验共同提示FTZ通过调节PI3K-AKT和HIF-1α信号通路对T2DM伴NAFLD产生治疗作用。

研究设计与样本

  • 研究采用网络药理学预测FTZ的活性成分与靶点,并在T2DM伴NAFLD小型猪模型中进行验证。

主要发现

  • 共鉴定出116个活性化合物和82个与T2DM及NAFLD相关的潜在靶点。
  • 通路富集分析显示FTZ主要调节代谢相关通路,包括PI3K-AKT、HIF-1α、TNFα和MAPK。
  • 动物实验显示FTZ显著降低血清TG、TC、LDL-C和FBG,升高HDL-C,改善全身胰岛素抵抗并减轻肝损伤。
  • 组织病理学(HE、油红O染色和电镜)显示FTZ明显改善肝脏脂肪变性和脂质积累。
  • 机制上FTZ增加PI3K-AKT磷酸化并降低HIF-1α表达,从而改善肝脏代谢。

临床怎么用

  • 对于T2DM合并NAFLD患者,FTZ可能作为改善糖脂代谢和肝脏脂肪变的候选中药复方,但需临床研究进一步验证。

局限性

  • 研究仅基于网络药理学预测和小型猪模型验证,尚未在人体临床试验中证实其疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Fufang Zhenzhu Tiaozhi formula (FTZ) of which a patented preparation of Chinese herbal medicine has been well documented with significant clinical curative effect for hyperglycemia and hyperlipidemia. Because of the complexity of the chemical constituents of Chinese herbal formulas, the holistic pharmacological mechanism of FTZ acting on type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) remains unclear. AIM OF THE STUDY: To investigate the pharmacological efficacy and mechanism of FTZ in the treatment of T2DM accompanied by NAFLD. MATERIALS AND METHODS: Network pharmacology and validation in minipigs were used in this study. First, potential bioactive compounds of FTZ were identified by the traditional Chinese medicine system pharmacology technology platform (TCMSP). Then, targets of compounds were gathered using DrugBank, SwissTargetPrediction and TCMSP, while targets for T2DM and NAFLD were collected from CTD (compounds-targets-diseases network) and GeneCards. Common targets were defined as direct therapeutic targets acting on T2DM with NAFLD. In addition, crucial targets were chosen by the protein-protein interaction (PPI) network and contribution to compound-therapeutic targets in T2DM with the NAFLD network. Furthermore, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the metabolism-related signaling pathways affected by FTZ. Candidate patterns selected by network pharmacology were tested in the minipigs model of T2DM with NAFLD. Measurements of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting insulin (FINS) and fasting blood glucose (FBG) in the blood and the expression levels of proteins, including PI3K-AKT and HIF-1α, in the livers of the minipigs were followed by the administration of FTZ. RESULTS: A total of 116 active compounds and 82 potential targets related to T2DM and NAFLD were found. Pathway and functional enrichment analysis showed that FTZ mainly regulates metabolism-related pathways, including PI3K-AKT, HIF-1α, TNFα and MAPK. Animal experiments showed that FTZ treatment significantly reduced the serum levels of TG, TC, LDL-C and FBG, increased serum levels of HDL-C, ameliorated systemic insulin resistance (IR), and attenuated liver damage in minipigs with T2DM and NAFLD. FTZ treatment has an obviously favorable influence on hepatic steatosis and liver lipid accumulation in the histopathologic features of HE, Oil red O staining, and electron microscopy. Mechanistically, FTZ improved liver metabolism by increasing the phosphorylation of PI3K-AKT and decreasing the expression of HIF-1α. CONCLUSION: Network pharmacology was supported by experimental studies, which indicated that FTZ has demonstrated therapeutic benefits in T2DM and NAFLD by regulating the PI3K-AKT and HIF-1α signaling pathways.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang H, Tan H, Zhan W, et al. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs. J Ethnopharmacol. 2021. PMID: 33771638. doi:10.1016/j.jep.2021.114056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。